IPO Performance Analysis: Why Most New Stocks Drop 27% in Year One
New research shows major IPOs frequently underperform in their first year, with historical data suggesting that hype often leads to unsustainable valuations…
New research shows major IPOs frequently underperform in their first year, with historical data suggesting that hype often leads to unsustainable valuations…
Enterprise Products Partners, Realty Income, and PepsiCo provide stable income streams and proven dividend growth, offering a defensive hedge against current geopolitical…
As market conditions turn shaky, investors are urged to review their IBD 50 holdings and execute sell orders for stocks triggering technical…
Investors concerned about high market valuations can hedge against potential downturns by utilizing defensive ETFs focused on essential sectors and reliable dividend-paying…
A performance comparison between SPGM and SCHE reveals distinct trade-offs between broad global equity exposure and targeted emerging market growth, with SPGM…
Rising interest rates are driving bond yields higher, creating a compelling entry point for income-focused investors who prioritize long-term cash flow over…
Investors are urged to exercise extreme caution with pre-IPO solicitations, as many lack transparency, involve complex indirect ownership structures, and are frequently…
Dave Ramsey argues that bond-heavy retirement portfolios are mathematically flawed, urging retirees to prioritize cash reserves over bond funds to sustain long-term…
Peter Schiff argues that the 7.76-cent metal value of U.S. nickels offers a better store of value than Treasuries, despite federal laws…
Meta Platforms emerges as the superior long-term investment over AppLovin, driven by its unmatched global user base and resilient advertising platform, even…
Market strategist Kevin Mahn argues that long-term investors should avoid the pitfalls of market timing, noting that missing the market's best days…
The iShares U.S. Healthcare ETF (IYH) provides a cost-effective, diversified core for portfolios, while the Invesco Biotechnology & Genome ETF (PBE) serves…